Pfizer has said it expects to lose $17 billion in annual sales between 2025 and 2030 due to patent expirations for top drugs, and sales of its COVID-19 products have begun to decline after they contributed to an unprecedented surge in revenue.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Or50gTD
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» 'Pfizer in talks to buy cancer drugmaker Seagen'
https://ift.tt/GiuK79S
No comments:
Post a Comment